Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zhongyuan Union Stem Cell Bioengineering Co announces FY 2013 net profit outlook


Thursday, 9 Jan 2014 07:00pm EST 

Zhongyuan Union Stem Cell Bioengineering Co:Sees net profit for the fiscal year (FY) 2013 to decrease by no more than 50 pct, compared to the net profit of the same period in FY 2012 (13.8989 million yuan).Says the reason for negative outlook is due to the increased financial cost, the increased amortization expense and the decreased stem cell storage. 

Company Quote